J&J beats quarterly sales and profit estimates on cancer drug sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
January 22, 2025 8:15 AM ESTRaymond James analyst Jayson Bedford reiterated an Outperform rating and $170.00 price target on Johnson & Johnson (NYSE: JNJ)
The analyst comments "Quick take: 4Q results were solid with a 1% revenue beat and a 3% EPS beat. The revenue upside was driven by Innovative Medicine... More
